Search Results

You are looking at 1 - 10 of 11 items for :

  • Willingness-to-Pay x
  • Clinical Medicine, other x
Clear All
Open access

Hristo P. Dobrev, Nikolay G. Atanasov and Donka D. Dimitrova

patients’ willingness to pay for dermatological and dental treatment. Journal of International Scientific Publications: Economy & Business 2013;7(2):219-28. 10. Drummond MF, O’Brien BJ, Stoddart GL, et al. [Methods for the economic evaluation of health care programs.] 2nd ed. Sofia: MF; 2007:289-94 (in Bulgarian). 11. McIntosh E, Clarke PM, Frew EJ, et al, eds. Applied methods of cost-benefit analysis in health care. Oxford: Oxford University Press; 2010:127-38. 12. Edejer TT, Baltussen R, Adam T, et al, editors. Making choices in health: WHO Guide to

Open access

Zlatina I. Ivanova and Yavor Y. Ivanov

willingness to pay in asthma. Pharmacoeconomics 2002; 20(4): 257-65. 29. Castaldi P, Rogers W, Safran D, et al. Inhaler costs and medication nonadherence among seniors with chronic pulmonary disease. CHEST 2010; 138(3): 614-20. 30. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61-7. 31. Ayres J, Boyd R, Cowie H, et al. Costs of occupational asthma in the UK. Thorax 2011; 66: 128-33. 32. Kauppinen R, Sintonen H, Vilkka V, et al. Long-term (3-year) economic

Open access

Adawan Permpanich, Vithaya Kulsomboon and Kamol Udol

QALY and 256,199 THB per LYG ( Table 3 ). ICER/QALY and ICER/LYG reduced when the patients had MI at the older age, indicating that the addition of n-3 PUFAs is more cost-effective in elderly patients than in younger patients ( Figure 3 ). The probability of cost-effectiveness at different levels of willingness-to-pay in different ages of the patients is shown in Figure 4 . Figure 3 Incremental effectiveness of n-3 PUFAs supplementation at different ages of post-MI patients Figure 4 Cost-effectiveness acceptability curve of n-3 PUFAs

Open access

Yuwadee Leelukkanaveer, Pornchai Sithisarankul and Narin Hirunsutthikul

:464-9. 8. Ormaasen V, Sandvik L, Dudman SG, Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis. 2007; 39:51-7. 9. Garcia F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004; 36:702-13. 10. Egger M, May M, Chene G, Phillips AN, Ledergerber

Open access

Pongphaya Choosakulchart, Tanattha Kittisopee, Suchet Takdhada, Yoel Lubell and Janet Robinson

:// 8. Hoerger TJ, Hicks KA, Bethke AD. Health, social, and economics research; technical report: a Markov model of disease progression and cost-effectiveness for type 2 diabetes. NC; 2004. 9. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. AJPH. 1987; 77:1417-26. 10. Board of directors to reduce the risk factors that affect chronic disease. Thailand healthy lifestyle strategic plan 2011-2010: situation of

Open access

. We now provide a greater level of detail describing the various elements of most manuscripts to guide authors composing a manuscript, paying special attention to the presentation of data, including that in Tables and Figures. We hope that the new Guide will provide greater publication integrity by raising the awareness of our authors and reviewers to internationally recognized requirements specified in our Guide, and lead to improvement of manuscripts submitted to us and articles published by us. In this Editorial we highlight some of the important points in our

Open access

Sudarat Lijutipoom, Somrat Lertmaharit and Piya Hanvoravongchai

. Results Of the 2,300 conference participants, 1,159 (50.4%) were willing to respond to the questionnaire. Of these respondents 1,149 (98.4%) provided completed answers. Among those respondents that provided completed answers, 1,072 (93.7%) already joined LHSFs and had conducted health promotion activities. Among the 1,149 respondents who provided completed answers, the ratio of men to women was almost 1 to 1. The mean age of the respondents was 43 years. About 77% had graduated with a Bachelor degree. The duration of work experience with the community was up to 13

Open access

Chi Chiu Mok, Hoon-Suk Cha, Emmanuel C Perez, Gregory J Tsay and Kam Hon Yoon

action taken by patients A total of 85% of patients took prescribed medications to relieve IMF, but 51% of patients did not find their current medications effective for relieving IMF. Only 14% of patients were satisfied with the efficacy of medications for IMF. Of the patients who did not take any medications for IMF, 68% were not aware of the availability of such medications. The majority of patients (81%) were willing to pay (up to US$1 per day) for medications to relieve IMF, if any. More than 70% of physicians would prescribe a marketed product for the

Open access

Yong Kang Cheah and Hock Kuang Lim

individuals are more prone to suffering from diseases because of the biological process of aging, they are more motivated to use health screening. Young people also tend to take their health for granted, and consequently ignore the importance of health screening [ 23 ]. Therefore, we suggest that policy makers pay special attention to young people rather than the elderly, if the goal of increasing the utilization of health screening, particularly blood glucose screening is to be achieved. Married individuals are more likely to use blood glucose screening than unmarried

Open access

Phantipa Sakthong, Vijj Kasemsup and Win Winit-Watjana

invited via mail to participate in the study and provide their telephone numbers. Only 901 patients were willing to take part in the study and half of them were further systemically sampled for a telephone interview. After excluding patients for various reasons, only 386 patients completed the study. All of them provided written informed consent to participate in this study. Figure 1 Study flow Study instruments Two generic instruments were used because, unlike disease specific tools, they are more flexible in terms of patient population and